Literature DB >> 29848284

Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD).

Kanisa Jampoka1, Puth Muangpaisarn2, Kritsada Khongnomnan1, Sombat Treeprasertsuk2,3, Pisit Tangkijvanich1,3, Sunchai Payungporn1.   

Abstract

BACKGROUND: Non-Alcoholic Fatty Liver Disease (NAFLD) is an over accumulation of triglyceride in the liver without alcohol consumption. Its major cause is insulin resistance. Patients with NAFLD can develop liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) are non-coding RNAs that regulate post-transcriptional gene silencing. Previous research reported that miR-29 family (a, b and c) and miR-122 have an important role in regulating insulin resistance related to NAFLD.
OBJECTIVE: The purpose of this study was to investigate that miR-29 and miR-122 can be possible biomarkers for non-invasive diagnosis of NAFLD.
METHOD: Serum samples were collected from 58 NAFLD patients and 34 healthy controls. MiRNAs were extracted from serum by using microRNA purification kit followed by polyuridylation, reverse transcription and quantitative real-time PCR. Also, we analyzed the correlation between miR-29 and miR-122 and level of liver inflammation in NAFLD patients.
RESULTS: We found that the serum miR-29a levels in NAFLD patients were significantly lower (P = 0.006) than the control group, while miR-29c levels were unchanged, and miR-29b levels were undetectable. However, we found that serum miR-122 levels in NAFLD patients were significantly higher (P < 0.001) than those found in the control group. For miR-29a, the area under curve (AUC) was 0.679 (P = 0.0065) with 60.87% sensitivity and 82.35% specificity. For miR-122, the AUC was 0.831 (P < 0.0001) with 75.00% sensitivity and 82.35% specificity. Interestingly, the levels of serum miR- 122 were significantly different between patients without steatohepatitis (NAS < 4) and steatohepatitis (NAS ≥ 4), indicating that the levels of miR-122 were related to the severity of NAFLD.
CONCLUSION: The levels of miR-29a and miR-122 might be beneficial and compelling as possible biomarkers for non-invasive diagnosis of NAFLD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Biomarkers; Non-Alcoholic Fatty Liver Disease (NAFLD); miR-122; miR-29a; microRNA; nucleus.

Mesh:

Substances:

Year:  2018        PMID: 29848284     DOI: 10.2174/2211536607666180531093302

Source DB:  PubMed          Journal:  Microrna


  27 in total

1.  Pro-Neurotensin as a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease.

Authors:  Amal A Mohamed; Dina M Abo-Elmatty; Omnia Ezzat; Noha M Mesbah; Nada S Ali; Aliaa Sayed Abd El Fatah; Eman Alsayed; Mahmoud Hamada; Alshymaa A Hassnine; Sherief Abd-Elsalam; Ahmed Abdelghani; Mohamed Badr Hassan; Shaimaa A Fattah
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-22       Impact factor: 3.249

Review 2.  Circulating MicroRNAs as a Tool for Diagnosis of Liver Disease Progression in People Living with HIV-1.

Authors:  Miguel Angel Martinez; Cristina Tural; Sandra Franco
Journal:  Viruses       Date:  2022-05-24       Impact factor: 5.818

Review 3.  NAFLD: Mechanisms, Treatments, and Biomarkers.

Authors:  Fatiha Nassir
Journal:  Biomolecules       Date:  2022-06-13

Review 4.  Factors influencing circulating microRNAs as biomarkers for liver diseases.

Authors:  Shalini R Dubey; Tester F Ashavaid; Philip Abraham; Minal Umesh Paradkar
Journal:  Mol Biol Rep       Date:  2022-02-20       Impact factor: 2.742

5.  Circulating Levels of microRNA-122 and Hepatic Fat Change in Response to Weight-Loss Interventions: CENTRAL Trial.

Authors:  Mengying Wang; Qiaochu Xue; Xiang Li; Knut Krohn; Stefanie Ziesche; Uta Ceglarek; Matthias Blüher; Maria Keller; Anat Yaskolka Meir; Yoriko Heianza; Peter Kovacs; Iris Shai; Lu Qi
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 6.  Sirtuin deficiency and the adverse effects of fructose and uric acid synthesis.

Authors:  Bernardo Rodriguez-Iturbe; Richard J Johnson; Miguel A Lanaspa; Takahiko Nakagawa; Fernando E Garcia-Arroyo; Laura G Sánchez-Lozada
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-03-10       Impact factor: 3.619

7.  The Circulating Micro-RNAs (-122, -34a and -99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases.

Authors:  Olfat M Hendy; Hatem Rabie; Amr El Fouly; Mohamed Abdel-Samiee; Nashwa Abdelmotelb; Amr Aly Elshormilisy; Mahmoud Allam; Samia Taher Ali; Nessren Mohamed Bahaa El-Deen; Shimaa Abdelsattar; Somia Mokabel Mohamed
Journal:  Diabetes Metab Syndr Obes       Date:  2019-12-19       Impact factor: 3.168

8.  High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients.

Authors:  Xiaomin Zhang; Fu'an Wang; Guangfeng Gu; Qingpo Wu
Journal:  J Oncol       Date:  2021-06-11       Impact factor: 4.375

Review 9.  Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance.

Authors:  Ariadna Pielok; Krzysztof Marycz
Journal:  Int J Mol Sci       Date:  2020-06-11       Impact factor: 5.923

Review 10.  The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond.

Authors:  Hung-Yu Lin; Ya-Ling Yang; Pei-Wen Wang; Feng-Sheng Wang; Ying-Hsien Huang
Journal:  Cells       Date:  2020-04-22       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.